A variety of proteases have been shown to promote the progression of cancer by virtue of their ability to degrade extracellular proteinaceous barriers, such as basement membrane and interstitial stroma. At the outset of this study available evidence strongly implicated cathepsin D in breast cancer metastasis. It was envisaged that an antibody inhibitory to the activity of this enzyme might retard invasion, and restrain a tumour from spreading. To this end anti-peptide antibodies were generated against a peptide sequence derived from the substrate capturing "flap" of the enzyme. Inhibition of enzyme activity by these antibodies could not be demonstrated, probably due to the lack of a suitably sensitive enzyme assay. However, the rationale of this study and the expertise gained from it could be applied, in the future, to enzymes that have since been found to be more relevant to tumour invasion. A feature of many transformed cells is an anomalous lysosomal enzyme trafficking system, and concomitant hyper-secretion of some enzymes. The distribution of low pH compartments and lysosomal enzyme-containing compartments was investigated in human breast epithelial cells, and their c-Ha-ras- transformed counterparts. Immunofluorescence and immunoelectron microscopy showed that these compartments have a more peripheral cellular distribution with respect to normal cells, and cathepsins B and D were cell surface-associated. Studies were undertaken to reveal the extracellular matrix degrading ability of c-Ha- ras-transformed cells. Transformed cells exhibited increased degradation of fluorescein-labelled extracellular matrix in serum free medium, and increased motility, and degradation and disruption of extracellular matrix in serum-containing medium. In vitro invasion through artificial basement membrane by transformed cells was investigated using scanning electron microscopy, and was further used to preliminarily identify the proteases involved in invasion by specific inhibition. By this means, greatest inhibition of in vitro invasion was obtained using a specific metalloproteinase inhibitor. Overexpression by transformed cells of a metalloproteinase was detected by gelatin zymography. Together these results suggest that the increased invasive capacity of ras-transformed breast epithelial cells may be largely due to increased metalloproteinase activity. / Thesis (Ph.D.)-University of Natal, Pietermaritzburg , 1996.

Protozoan parasites of the genus Trypanosoma are responsible for chronic and widespread disease in livestock and humans in Africa. This study describes the purification and characterisation of a serine oligopeptidase from Trypanosoma brucei brucei and from T. congolense. Serine peptidase activity has previously been described for T. b. brucei although the responsible enzyme was not purified to electrophoretic homogeneity. In the present study this enzyme was purified from bloodstream-form T. b. brucei by a combination of three-phase partitioning, ion-exchange, affinity and molecular exclusion chromatography. Characterisation of the enzyme revealed that it closely resembled a bacterial serine oligopeptidase, Escherichia coli oligopeptidase B, in terms of cleavage-site specificity, inhibition characteristics and molecular mass. Its overall properties indicate that it is probably a serine oligopeptidase and we have called it OP-Tb (oligopeptidase from Trypanosoma brucei). Antibodies to OP-Tb were prepared in chickens. These antibodies were used in the purification of a similar enzyme, designated OP-Tc, from T. congolense. OP-Tc closely resembled OP-Tb in its enzymatic properties. OP-Tb appears to be monomeric, with an apparent molecular mass of 80 kDa. Activity is optimal between pH 8.0 and 10.0, and is enhanced in the presence of reducing agents. Inhibition by 4-(2-aminoethyl)benzenesulfonylfluoride, 3,4-dichloroisocoumarin and diisopropylfluorophosphate indicates that the enzyme may be classified as a serine protease. While various natural and synthetic fluorogenic peptide substrates were hydrolysed by OP-Tb, larger potential substrates (proteins) were not. Studies of the digestion of naturally occurring bioactive peptides suggested that substrates were restricted to peptides smaller than approximately 4 or 5 kDa. These peptides were cleaved at the carboxy side of basic amino acid residues such as arginine and lysine. This is characteristic of a trypsin-like specificity. Because the enzyme is known to be readily released from the parasites, and because it was possible to detect OP-Tb-like activity in the blood of T. b. brucei-infected mammalian hosts, it appears that the enzyme is released into the host bloodstream where it remains uninhibited by endogenous protease inhibitors. Indeed, OP-Tb was not inhibited by mammalian plasma serpins or 012-macroglobulin in vitro. This, and the degradation of host peptide regulatory hormones in vitro, suggests that OP-Tb may have secondary, but important, extracellular roles in the pathogenesis of African trypanosomiasis. A variety of serine protease inhibitors, including inhibitors of OP-Tb were tested for their potential as trypanocidal agents. The results from both in vitro and in vivo studies, suggest that inhibitors of trypanosome oligopeptidases are promising new lead targets for drug development. Furthermore, data presented here also shows that OP-Tb is efficiently inhibited by several of the currently employed trypanocidal drugs. Thus, OP-Tb may already be a cellular target for trypanocidal drugs. If correct, this may represent an important step towards understanding the biochemical mechanisms of the trypanocidal activity of these drugs, as well as providing valuable clues as to how to improve their efficacy. / Thesis (Ph.D.)-University of Natal, Pietermaritzburg, 1998.

Infectious bursal disease virus (IBDV) causes an acute and highly contagious disease affecting young chickens, which is responsible for significant losses in the poultry industry world-wide. The virus specifically infects and destroys B-cell precursors within the bursa of Fabricius, an avian lymphoid organ, leading to immunosuppression. IBDV has a bi-segmented, double-stranded RNA genome. The larger segment encodes a 110-kDa precursor polyprotein, designated NH₂-VPX-VP4-VP3-COOH, in a single open reading frame. The autocatalytic processing of this precursor into mature proteins is a critical step in viral replication and VP4 is the putative protease responsible for this cleavage. This study concerns the development of a strategy to clone and express recombinant VP4 and describes the use of VP4 as a marker for rapid and effective detection of IBDV. VP4 cDNA was produced and amplified by optimisation of a reverse transcription coupled to the polymerase chain reaction (RT-PCR), providing a clear and sensitive assay. Anti-peptide antibodies were raised against a selected peptide from VP4 and were used to probe homogenates of infected bursae for the native protein to assess their potential for immunological detection. These antibody-related results are promising though inconclusive, due to the complex nature of the assayed sample. Amplified VP4 cDNA from KwaZulu-Natal strains of IBDV isolated from 1989 to 1997 was also examined by restriction fragment length polymorphism (RFLP) analysis to determine the relatedness of local IBDV to global strains. All KwaZulu-Natal samples produced identical patterns, which were most similar to one of ten international strains examined, namely, the British strain UK661. Samples infected with IBDV were also probed for VP4 activity. Double basic amino acid cleavage sites have been proposed for the putative protease and infected samples were assayed for activity against the fluorogenic peptide Cbz-Arg-Arg-AMC. Demonstrably higher activity was found in infected versus uninfected samples, although the origin of this activity is unclear. The findings in this study suggest that VP4 warrants further attention, both as a marker for infectious bursal disease, and as a novel viral protease. / Thesis (M.Sc.)-University of Natal, Pietermaritzburg, 2000.

The protozoan parasite Trypanosoma congolense is one of the aetiological agents of African animal trypanosomiasis that is transmitted by the tsetse fly. The parasite causes nagana in animals and affects livestock throughout sub-Saharan Africa. The toxicity of available drugs and the emergence of drug resistant parasites have affected the treatment of trypanosomiasis. Control of the disease has also been difficult due to ineffective vector control and the potential of trypanosomes to express hundreds of antigenetically distinct proteins on their surface. Vaccination against trypanosomiasis has been thought to be a possible control method. Since a vaccine based on variable surface proteins of the parasite is unlikely, research has been directed towards the identification of invariant pathogenic factors of the parasite as potential targets for therapy. Congopain, the major cysteine protease of T. congolense has been implicated in the pathology of the disease. Antibodies against congopain are known to contribute to the mechanisms of natural resistance to trypanosomiasis known as trypanotolerance by neutralising the pathogenic effects of the enzyme. Oligopeptidase B (OpdB), a trypanosomal serine protease has also been associated as a pathogenic factor of the disease. It is released into the host’s circulation by dead or dying parasites and retains its catalytic activity since it is insensitive to host serum inhibitors. In the present study, the catalytic domain of congopain (C2) and the use of alpha-2-macroglobulin (α2M) as an adjuvant were investigated for their potential use in an anti-disease vaccine. α2-Macroglobulin has been used to varying degrees to target different antigens to cells of the immune system and enhance their immunogenicity. A previous study showed that antibodies raised in rabbits against C2 complexed to α2M gave a higher percentage inhibition than antibodies made using C2 mixed with Freund’s adjuvant. In the present study, goats were immunised with C2 complexed with α2M to confirm the enhanced immunogenicity of C2 and the production of anti-C2 antibodies with superior inhibitory properties. Following immunisation, goats were challenged with T. congolense (strain IL 1180) and showed sustained antibody production during the two month infection period. Goat antibodies made using C2 in complex with α2M inhibited the hydrolysis of hide powder azure by C2 by 96%. Maximum inhibition of the hydrolysis of azocasein was observed to be 63% and hydrolysis of Z-Phe-Arg-AMC by C2 was inhibited by 73%. In order to determine the vaccine potential of OpdB, protein was recombinantly expressed as a glutathione-S-transferase fusion protein in the pGEX expression system and purified by glutathione agarose affinity chromatography and molecular exclusion chromatography. Since a small yield of protein necessitated several rounds of expression and extensive purification, OpdB was subsequently expressed as a His-tagged fusion protein in the pET bacterial expression system. Recombinant protein was easily purified using nickel chelate affinity chromatography. Purified OpdB was used with alum for the immmunisation of mice to produce antibodies capable of inhibiting enzyme activity. Following immunisation, mice were challenged with T. congolense (strain IL 1180) and also showed sustained antibody production following two months infection. Since all mice died, the administration of OpdB conferred no protection; however, anti-OpdB mouse antibodies inhibited 86% of OpdB activity against the substrate Z-Arg-Arg-AMC. In addition immunised mice were observed to survive 40% longer than control mice as they had previously been immunised with OpdB and were able to mount a rapid immune response against this pathogenic factor during infection. In general it could be concluded that immunisation of goats with C2 in complex with α2M produced antibodies with superior inhibitory properties. The immunisation of mice with OpdB and alum also produced inhibitory antibodies and previous administration of OpdB enabled mice to mount a rapid immune response against OpdB during infection. Antibody mediated enzyme inhibition demonstrates the potential use of C2 and OpdB as vaccines that may contribute to the development of an effective anti-disease vaccine. / Thesis (M.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2008.

Bibliography: leaves 118-130 / v, 130 leaves, [23] leaves of plates : ill ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Thesis (Ph.D.)--University of Adelaide, Dept. of Biochemistry, 1984

Thesis (Ph. D.)--Ohio State University, 2007. / Title from first page of PDF file. Includes bibliographical references (p. 152-161).

Thesis (Ph. D.)--West Virginia University, 2008. / Title from document title page. Document formatted into pages; contains viii, 173 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references.

Thesis (M.Sc.)--University of Alberta, 2010. / A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science, Department of Psychiatry. Title from pdf file main screen (viewed on February 14, 2010). Includes bibliographical references.

Thesis (Ph.D.)--University of Western Australia, 2008.

A disintegrin and metalloprotease (ADAM) 17 cleaves and releases membrane-tethered pro-forms of several signalling molecules from the plasma membrane, including the inflammatory cytokine tumour necrosis factor alpha (TNFα) and ligands of the epidermal growth factor receptor (EGFR). Due to the important functions of its substrates, ADAM17 activity has to be tightly controlled, and its misregulation has implications for inflammation and cancer. The multi-pass membrane proteins iRhom1 and iRhom2 are members of the conserved rhomboid-like superfamily and control ADAM17 activity by several mechanisms throughout the secretory pathway. First, iRhoms facilitate trafficking of the catalytically inactive proenzyme form of ADAM17 from the endoplasmic reticulum (ER) to the Golgi apparatus, where the inhibitory pro-domain of ADAM17 is removed. Subsequently, iRhoms exert a different form of control of ADAM17 at the plasma membrane, this time on stimulus-induced ADAM17 activity, its substrate specificity, and its stability. iRhoms ultimately regulate the release of ADAM17 substrates, and are consequently key players in TNFα and EGFR signalling. However, it remains unclear how iRhom function itself is regulated posttranslationally, and whether iRhoms require co-factors to exert their roles as ADAM17 regulators. The goal of my project was to shed light into these questions by identifying new iRhom interaction partners. I developed a mass spectrometry-based screen to identify new binding partners of human iRhoms using co-immunoprecipitation. The top hit of the screen was the poorly characterised FERM domain-containing protein 8 (FRMD8), which binds to both iRhom1 and iRhom2. FRMD8 was found to play a crucial role in the iRhom/ADAM17 pathway because FRMD8 knockdown and knockout in HEK293T cells significantly reduced the levels of mature ADAM17 and the release of ADAM17 substrates. The closely related metalloprotease ADAM10 was not affected by the loss of FRMD8, implying that FRMD8 is not a general regulator of ADAM metalloproteases. Interaction studies revealed that FRMD8 binds to the cytosolic N-terminus of iRhom2 throughout the entire secretory pathway. FRMD8 loss does not affect the ER-to-Golgi trafficking of iRhom2 but plays a role in stabilising iRhom2 at the plasma membrane by preventing the lysosomal degradation of both iRhom2 and mature ADAM17. Using human induced pluripotent stem cell (hiPSC)-derived macrophages, I showed that FRMD8 regulates mature ADAM17 levels and the ADAM17-dependent release of TNFα in human macrophages. Studies in FRMD8 knockout (KO) mice confirmed the reduced mature ADAM17 levels in all mouse tissues tested, further supporting the conclusion that FRMD8 is a novel regulator of the iRhom/ADAM17 pathway with physiological relevance in mammals. Finally, I showed that the interaction of FRMD8 and iRhom, which are both conserved from Drosophila to human, is also conserved. Furthermore, loss of the FRMD8 orthologue in flies, Bili, leads to motility defects and shows similarity to the loss of iRhom in flies. These results suggest that FRMD8 is a novel regulator of iRhom function in mammals and Drosophila.